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Modifications of calciuria and phosphaturia following glucose
ingestion in patients with calcium urolithiasis. J. Aubert, A. Ui-
mann, B. Lacour, and J. L. Funck-Brentano. Département de
Néphrologie, Hdpital Necker, Paris, France. Increased urinary
calcium excretion in patients with calcium urolithiasis could be,
at least in part, dependent on carbohydrate intake. To test this
hypothesis, we administered to 8 hypercalciuric stone-formers
(HCI), 8 normocalciuric stone-formers (Nd), and 7 control sub-
jects a 75-g glucose oral load, after they were fasted overnight.
Urine was collected during three 30-mm periods (one control pe-
riod, before glucose ingestion and two experimental periods 30 to
60 and 60 to 90 mm after glucose ingestion). High urine output
was obtained by infusing physiologic saline. Plasma samples
were collected at the middle of each period. Calcium, phos-
phorus, creatinine and sodium were measured in each plasma
and urine sample. In some patients, plasma I,25(OH)2D was as-
sayed before and after glucose ingestion. Results obtained after
glucose ingestion are as follows: (1) In patients with HCI, both
ClCaIClN, and ClcJClcreat significantly increased (P < 0.01). In
patients with NCI, Clc/C1creat but not ClCa/ClN increased signifi-
cantly (P < 0.01). In control subjects, neither Cla/Clcret nor
ClC'ClNa increased. (2) Although plasma phosphorus significant-
ly decreased in the three groups, TmP/GFR decreased in patients
with HCI (P < 0.05) or NC! (P < 0.01) but not in control sub-jects. (3) In patients with HCI in whom it was assayed,
1 ,25(OH)2D increased significantly. In conclusion, a glucose load
induces hypercalciuria in stone-formers with HCI or NC! and
contributes to high plasma !,25(OH)2D concentrations found in
these patients.
Nephrotic syndrome associated with T-cell lymphoma. D. Bel-
ghiti, J. P. Vernant, G. Hirbec, M. C. Gubler, C. André. and A.
T. Sobel. Hôpital Henri Mondor, Créteil, France. It has been
known for years that nephrotic syndrome may be associated with
malignant lymphomas. In the vast majority of the reported cases,
the glomerular disease was of the minimal-change type, and the
corresponding hematologic trouble was Hodgkin's disease. In
contrast, glomerulopathies associated with non-Hodgkin's lym-
phomas (NHL) have been rarely observed, and the cell type of
the lymphoproliferative disorder was never determined. This is
the first case of glomerular disease in a patient with NHL of
proven T-cell origin. I)ata obtained by functional assays, cyto-
chemical staining, and EM were consistent evidence indicating
that the lymphoproliferative disorder observed in a 17-year-old
black female, with early clinical involvement of liver and spleen
and secondary medullar infiltration, was a T-cell derived NHL.
The evidence included: E rosette formation with blast cells, ab-
sence of surface immunoglobulins and EAC rosettes, positive
staining for /3-glucuronidase and ultrastructural aspect on EM
examination. Nephrotic syndrome appeared shortly after the ap-
parent onset of NHL. The kidney biopsy specimen was exam-
ined by light, fluorescence, and electron microscopy. Histologic
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findings were consistent with the diagnosis of mild focal glomeru-
losclerosis. The lymphoproliferative disease responded partly
and transiently to combined chemotherapy without simultaneous
improvement of the nephrotic syndrome. This report supports
the concept of an eventual link between T-cell abnormalities and
glomerular diseases but more information is obviously needed to
assess such a hypothesis.
Effects of nonsteroidal antiinfiammatory drugs on the renin re-
lease by isolated perfused kidney. D. Casellas, M. Dupont, and A.
Mimran. CHR Saint-Charles, Montpellier, France. In vivo inhi-
bition of renal prostaglandmn (PG) synthesis by nonsteroidal anti-
inflammatory drugs (NSAID) is associated with a decrease in re-
nm release (RR) in various species including the rat. To elucidate
the mechanism(s) of action of such drugs, we assessed the effect
of indomethacin (I) and aspirin (AS) on RR by the isolated per-
fused rat and rabbit kidney. A cell-free medium was perfused at
the constant flow rates of 5 and 10 ml/min in rats and rabbits,
respectively. Perfusion pressure (PP) and renin concentration
(RC) in venous effluent were measured. In addition, NSAID ve-
hicle per se (NaHCO3) had no effect on either RC or PP in control
studies; effectiveness of PG synthesis inhibition by the presently
used doses of NSAID was checked (radioimmunoassay of PGE2
in venous effluent). In 7 rats, I was found to have a biphasic
effect on RC (a) at the dose of 0.55 M, RC was decreased by 22
3% and PP slightly increased by 2 0.5 mm Hg, (b) higher
doses of 1(5.5 to 167 M) increased RC (from 37 12% to 177
39%) without change in PP. In 4 rabbits, 27 to 139 .tM of I in-
creased RC by 167 27% to 612 90% with no change in PP. In
addition, in 7 rats, AS (55 M) induced a 22 3% decrease in RC
with slight increase in PP. Higher doses of AS (550 to 1110 /LM)
had no significant effect on RC and PP. These results demon-
strate that in the rat RR was decreased at a dose of I that is
known to act primarily on PG synthesis, and RR was increased at
higher doses known to inhibit phosphodiesterase (PDE) activity.
AS which does not inhibit PDE activity acted similarly to a low
dose of!. These findings could be further substantiated using a
potent PDE inhibitor, theophylline. In conclusion, the use of
NSAID to explore the role of PG synthesis inhibition alone must
be undertaken with caution.
Hypolipemic effect of d,l-carnitine in chronic hemodialysis pa-
tients. S. Di Giulio, B. Lacour, J. Chanard, C. Ciancioni, B. Leb-
kin, M. Haguet, C. Parry, C. Basile, and T. Drüeke. Hôpital
Necker, Centre E. Rist, Clinique de IA/ma, AURA, Paris and
CHU Reims, France. Hypertriglyceridaemia (HTG) in hemo-
dialysis patients may be associated with carnitine deficiency.
Carnitine is necessary for intramitochondrial transfer and oxida-
tion of free fatty acids and thus for prevention of HTG. In the
present multicentre study, 51 chronic hemodialysis patients with
HTG were given a daily oral dose of 2.4 g d,i-carnitine during 30
days to investigate a possible hypolipaemic effect. No patients
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had been on oral contraceptives, and none were alcoholics or
had obesity, diabetes, or other endocrinopathies. After 30 days
of d, / -carnitine treatment, the mean SEM serum triglycerid
(TG) concentration decreased significantly from 3.5 0.39 to
2.87 0.27 mmoles/liter (P < 0.02) in all pts. However, serum
total cholesterol did not change but HDL cholesterol increased
significantly from 0.89 0.05 to 1.35 0.07 mmoles/liter (P <
0.001). When analyzing the patients in terms of treatment effica-
cy, we found that two groups could be distinguished: 38 patients
(74%) had a decrease in serum TG concentration during d,l-car-
nitine treatment ("responders") from 3.75 0.52 to 2.66 0.35
mmoles/liter. However, 13 patients (26%) had no change or even
an increase. The administration of d,l-carnitine led to a signifi-
cant decrease of serum triglycerides in hemodialysis patients,
possibly via the correction of carnitine deficiency.
Proteinuria and anionic sites in the glomerular basement mem-
brane. M. Doriaux, R. Van Holder, J. Sennesael, and P. P.
Lambert. Fondation Médicale Reine Elisaheth, Bruxelles, Bel-
gique. Canine albumin (Sigma Chem. Co.) was cationized ac-
cording to Dannon et al (P.1. > 8.5). We infused 12 to 33 mg in
the left renal artery per mm and per 100 g of kidney weight during
15 to 200 mm. Transitory anuria in the left kidney was observed
in three dogs. On the average, left GFR decreased 60% and right
GFR 10%, PAH clearance decreased 64 and 24% respectively.
On the left side, proteinuria (> 1 mg/mm) appeared in six dogs;
on the right side in three dogs. Protein excretion appeared
earlier in the perfused kidney; it averaged 3.2 mg/mm compared
with 3.4 mg/mm in the contralateral kidney. Electron microscopy
showed in both kidneys the formation of clump-like deposits on
both sides of the glomerular basement membrane. The clumps
were more regularly distributed on the epithelial border than on
the endothelial border, producing on tangential slices a lattice-
like pattern comparable to that observed using other elec-
tropositive tracers. The degree of labeling of the anionic sites
varied from one kidney to the other, being more pronounced
when proteinuria was present. Nevertheless, a discrete clump
formation was occasionally observed in the contralateral kidney
when protein excretion remained below 1 mg/mm. Neither clump
formation nor proteinuria could be produced by intrarenal in-
fusion of anionic canine albumin at equivalent dose.
The kidney in systemic seleroderma: A study of 38 consecutive
cases. B. Francois, G. Moulin, H. Assenat, and B. Jandot. Renal
Section, Dermatology Section, Hôpital de l'Antiquaille, 69005
Lyon, France. The renal status of 38 patients with progressive
systemic scleroderma was investigated by the usual clinical
tests, urine immunoelectrophoresis, PAH, and inulin or '251-io-
thalamate clearances and in 4 cases a renal biopsy. Fourteen pa-
tients presented with proteinuria and/or a high serum creatinine
and/or hypertension, with low clearance values in all cases. In 14
other patients, an abnormality was apparent from clearance re-
suits (12 cases), renal biopsy (1), urine immunoelectrophoresis
(1). The earliest sign of renal involvement that could be demon-
strated was a reduced renal plasma flow as determined by the
PAH clearance and an elevated filtration fraction. A glomerular
mininal change electrophoretic pattern seemed to appear sub-
sequently as either isolated (9 cases) or associated with abnormal
clearance values (8 cases).
Plasma exchange therapy in steroid-resistant kidney allograft re-
jection. G. Fruchaud, A. A. Cattaneo, M. Fabre, T. Nebout, A.
T. Sobel and B. Weil. Department of Nephrology and Plasma
Exchange Committee, Hdpital Henri Mondor, Creteil, France.
Plasma exchanges (PE) have been used as additional treatment
of acute and subacute rejection crises of kidney allografts. The
overall benefit of this treatment has been previously difficult to
assess because of the lack of satisfactory criteria in highly heter-
ogeneous groups of patients. In this report we tried to reevaluate
PE therapy as part of the therapeutic approach of renal trans-
plantation. The effect of PE therapy was assessed only by con-
sidering the outcome of each allograft, particularly with regard to
the interval before resumption of hemodialysis (CH), when this
occurred. Nine patienis were given 11 sets of PE (fresh frozen
plasma exclusively) with an average of 7 PE per patient. PE were
performed when an acute or subacute rejection crisis occurred,
that was resistant to at least 4 days of high doses prednisolone (>
2 mg/kg/day) and/or methylprednisolone boli (750 mg). The dura-
tion of transplantation before the first PE averaged 133 days
(range, 8 to 456 days). Five patients recovered a fair renal func-
tion (mean creatinine, 198 iimoles/liter) that appeared stable 193
days after PE (52 to 492 days). Four patients without any im-
provement of renal function had to resume CH 192 days after the
crisis onset (range, 8 to 226 days). Six patients who were com-
parable in terms of graft duration until the rejection crisis and
response to steroid treatment were not given PE. All 6 patients
had to resume CH 100 days later (range, 5 to 255 days). The data
suggested that (1) PE may sometimes provide an alternative pro-
cedure for recovery of steroid resistant rejection crisis; (2) when
the response is not satisfactory, PE may delay CH for as much as
3 months (financial saving US $10,000 per patient).
Experimental approach to the treatment of lupus nephritis by
use of an accelerated model of NZBxNZW mouse disease. M. Gay-
ral-Ta Minh, G. J. Fournié, M. Mignon-Conte, andJ. J. Conté.
Laboratoire d'Immunopathologie Rénale, Service de Néph-
rologie et d'Hemodialyse. C. H. U. Toulouse-Purpan Tou-
louse-Cedex, France. The NZBxNZW mouse model has been
widely used to evaluate the effects of various drugs on lupus
nephritis. The aim of the present study was to develop an accel-
erated model of NZBxNZW mouse disease and to establish
whether it was suitable for therapeutic studies. For this purpose,
the effects of early immunization with DNA and of injection of
bacterial lipopolysaccharide (LPS) on the glomerulonephritis of
NZBxNZW mice were studied. Combined injections of DNA
complexed to methylated bovine serum albumin (DNA-mBSA)
and of LPS appeared to be more efficient in accelerating the dis-
ease of NZBxNZW mice than injections of DNA-mBSA or LPS
alone. A rapid increase in levels of anti-DNA antibodies, an early
appearance of severe renal lesions and a shortened survival were
observed in mice injected with both DNA-mBSA and LPS. Mice
with accelerated disease were treated with cyclophosphamide or
heparin. The efficacy of cyclophosphamide for the treatment of
the NZBxNZW mouse disease was shown by immunologic and
histologic studies in mice younger than 4 months. Heparin ap-
peared to have a beneficial effect by preventing the endocapillary
cellular proliferation induced by injections of DNA-mBSA and
LPS. The accelerated model of NZBxNZW mouse disease might
be a useful tool for experiments on the treatment of lupus nephri-
tis.
Passive-active immunization against hepatitis B in a high-risk
setting. N. Geslin, D. Pierre, P. Lebon, Ph. Maupas, P. Dubois,
A. Goudeau, P. Coursaget, G. Lesage, B. Yvarnet. Hopital
d'Orléans-La Source, Service d'hémodialyse, Orleans Cedex,
Hdpital du Mans, Service de Néphrologie-Hémodialyse, Le
Mans, Institut de virologie, Tours, France. Since 1975, immuni-
zation against hepatitis B in man was carried out by means of a
formalin-inactivated vaccine. This vaccine was proven to be safe
and effective in prevention of hepatitis B infection in high-risk
settings. In some volunteers, however, infections occurred be-
fore immunization was completed. Simultaneous administration
of specific anti-HBs antibody and hepatitis B vaccine was per-
formed to avoid such infections. This protocol is in fact similar
to that used for the prevention of rabies and tetanus. Passive-
active immunization has been applied to 11 staff members and 23
patients of a hemodialysis unit where hepatitis B was common.
Tn 100% of ward staff members and 56% of patients, it was pos-
sible to induce active immunization under specific protection
with anti-HBs immunoglobulins. This result is assessed by the
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persistance and/or increase of anti-HBs while passively acquired
antibodies disappeared as shown by the kinetics of anti-HBc.
Primary response to the vaccine is associated with anti-HBs in
the 1gM class in most of the cases. Passive-active immunization
remains the most effective preventive measure against hepatitis
B infection in hemodialysis units for individuals who are exposed
constantly to a high risk of infection.
Renal effects of ozoline, a new loop diuretic. J. L. Imbs, M.
Schmidt, and J. Schwartz. Institut de Pharmacologie, Facu/té
de Médecine, Strasbourg, France. The elimination of water and
electrolytes, free water clearance, renal blood flow, glomerular
filtration, and renin secretion were measured for 6 hours after the
iv. injection of 6 10 M/kg of (+)- or (—) -ozolinone (15.5 mg/kg)
or of forosemide (20 mg/kg) in 20 pentobarbitol-anaesthetized
dogs. (—)-Ozoline has the characteristics of a loop-diuretic and,
at equimolar doses, is more active than furosemide. Both ozoline
isomers provoke a large and prolonged rise in renal blood flow.
This renal vasodilation is accompanied by a drop in GFR and in
the filtered fraction, which suggests that the vasodilatory action
predominantly affects the efferent glomerular arteriole. Distin-
guishing between hernodynamic modifications and salidiuretic
response enables the effects of the two isomers to be analyzed,
and favors the study of the parameters involved in renin hyper-
secretion provoked by loop diuretics. Only (—-)-ozoline, a sa-
lidiuretic and vasodilator, provokes renin hypersecretion like
that induced by furosemide. (+)-Ozoline, which is only a vaso-
dilator, does not signilicantly modify renin secretion.
Influence of oral contraceptive therapy on lupus nephritis activi-
ty. P. Jun gers. M. Dougados. C. Pelissier, F. Kuttenn, F. Tron,
Ph. Lesavre, and J. F. Bach. Inserm U 25, Departments of
I'Jephrology and Endocrinology, Necker Hospital, Paris,
France. The deleterious effects of estrogens in experimental mu-
rine lupus are well established. We retrospectively studied the
relationship between oral contraceptive (OC) therapy and the ac-
tivity of lupus disease in 36 females with severe forms of system-
ic lupus erythematosus (SLE), observed at Necker Hospital
from 1974 to 1979. All patients had renal involvement, docu-
mented by renal biopsy in 32, of which 9 showed diffuse prolifer-
ative glomerulonephritis. Immunologic assessment of SLE (anti-
DNA binding, serum complement, PEG test, cryoglobulinaemia)
was performed every 3 months during the study period. Com-
bined preparations containing either 50 g (14 pts) or 30 g (7
pts) of ethinyl-estradiol were given to 21 women. Initial signs of
SLE developed inS of them, and exacerbation of quiescent SLE
in 6 others, during the 3 to 24 months following the start of OC
therapy, an overall flare-up incidence of 52%. Pure progestogen
preparations were given as OC therapy to 11 pts, using continu-
ous microdose progestins (6 pts), low-dose norsteroids (3 pts) or
chlormadinone acetate (2 pts). With a followup of 6 to 27 months,
none of these patients developed clinical or immunologic signs of
SLE exacerbation. Similarly, sequential substitutive therapy
with percutaneous 17 beta-estradiol and chlormadinone acetate
was used in 4 women with persistent amenorrhoea following cy-
clophosphamide therapy, without any sign of exacerbation of
quiescent SLE (followup: 18 to 29 months). We conclude that
oral contraceptive therapy using estrogens, even at low dosage,
often induces exacerbation in SLE patients. In our experience,
pure progestins were effective and devoid of such deleterious ef-
fects, and should be preferred in these patients.
Plasma and urinary oxalic acid in normal subjects, in patients
with chronic renal failure and in patients treated by maintenance
hemodialysis. A. Krouri, C. Jacobs, G. Charransol, and J. P.
C/aye!. Groupe Hospitalier Pitié-Salpétrière, Paris, France. The
mechanisms of renal excretion of oxalic acid (OA) remain con-
troversial. Depending on the method used for measuring plasma
and urinary OA, renal clearance of OA is evaluated in normal
subjects between 10% and 200% of GFR. In this study, plasma
OA (measured by colorimetric method) and urinary OA (mea-
sured by gas-chromatography) are determined in 34 control sub-
jects (17 males, 17 females) with normal GFR (creatinine clear-
ance, 109 14 mL/mn), in 3 groups of 8 patients each with CRF
whose average Ccr are 34.6 9.6 (group 1), 15.2 2.4 (group 2),
and 8.04 1.8 mm (group 3) and in 16 patients treated by mainte-
nance hemodialysis. In the control-subjects, mean plasma level
of OA is 28.4 8 moles/liter (2.56 0.72 mg); 24 hours urinary
OA, 324 67 moles/liter (29.2 6 mg); and mean renal OA
clearance, 9.06 3.3 mllmin. A significant rise of plasma OA (49
6.3 moles/liter, P < 0.001), a significant decrease of 24 hours
urinary OA (262 81 moles/liter, P < 0.05), and of renal clear-
ance of OA (4.14 1.2 mI/mm, P < 0.001) compared lathe val-
ues found in the control subjects is recorded only in patients with
an advanced stage of CRF (group 3). In 8 patients treated by
maintenance hemodialysis 15 hours per week with cuprophane
membrane dialyzers and a single-pass dialysis fluid delivery sys-
tem, mean plasma OA is found at 77 17 mo1es/liter before
dialysis, 39 5 moles/liter after dialysis, the extraction rate of
OA during dialysis being 50.8%. In 8 patients dialyzed 9 to 12
hours per week with PAN membrane dialyzers and a closed-loop
batch dialysis fluid delivery system, plasma OA is found at 102
32 before dialysis and 51 19 moles/liter after dialysis, the ex-
traction rate during dialysis being 49.8%. The differences of the
values recorded in the two groups of dialyzed patients are not
statistically significant. These results are at variance with those
reported in the literature by the authors who use isotopic meth-
ods with '4C oxalate to evaluate urinary and plasma OA. Isotopic
methods yield much lower values for plasma OA, the renal clear-
ance of OA being thereby found higher than GFR. The steady
elevation of the fractional excretion of OA (OA clearance ÷
creatinine clearance) until the advanced stage of CRF is attrib-
uted to a sharp decrease of the reabsorption of OA in the proxi-
mal convulated tubule, rather than to an increase of tubular se-
cretion.
Influence of sodium and potassium intake on renal adaptation to
a chronic acid load. J. J. Lafontaine, E. Munoz, J. P. Dieu, and
C. van Ypersele de Strihou. Université Catholique de Louvain,
Cliniques Universitaires St-Luc, Service de Néphrologie, Bru-
xelles, Belgium. Renal response to a chronic acid load (CAL) is
not modified by the presence or absence of dietary sodium chlo-
ride, an observation arguing against the concept that sodium
availability in distal tubule (DT) is a determinant of renal acid
excretion. Sodium chloride might have, however, a twofold ef-
fect: increased sodium availability in DT and extracellular fluid
expansion decreasing I)T avidity for sodium. In the present
study, we have prevented extracellular fluid expansion by pro-
viding sodium and hydrogen ions with a nonreabsorbable anion
sulfate. Simultaneously, the role of potassium was assessed by
evaluating the influence of sodium with and without concomitant
potassium depletion. Twenty-one dogs, potassium depleted with
an electrolyte-free diet and Kayexalate, are given a CAL (3.5
mm/kg/day) of ammonium sulfate. In group A (12 dogs), no so-
dium is given; in group B (9 dogs) sodium sulfate (1.25 mg/kg/
day) is added to the diet. After CAL (period I), plasma bicarbo-
nate is lower in group A than it is in group B (14.8 vs. 19.7; P <
0.01). Sodium intake is thus a critical determinant of the re-
sponse to CAL. Correction of the potassium deficit by the addi-
tion of potassium sulfate (1.25 mg/kg/day) (period II) increases
plasma bicarbonate in both groups (+ 2.4 and 3.8 mEq/liter),
confirming thus the existence of potassium deficiency acidosis.
Provision of sodium sulfate to 4 potassium-repleted animals
(group A, period III) increases further plasma bicarbonate (+ 8.1
mEq/liter), demonstrating that the renal response to CAL re-
mains sodium dependent even after potassium repletion. We
conclude (1) distal tubular sodium is a critical determinant of the
renal adaptation to CAL independently of potassium balance (2)
potassium deficiency acidosis persists even when the acid load is
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given with a nonreabsorbable anion. It does not result from an
increased tubular permeability to chloride.
Tuberous sclerosis with chronic renal failure treated by hemo-
dialysis and transplantation. A. Meyrier, M. Rainfray, and J. Ro-
land. Service de Néphrologie, Hôpital, Tenon, Paris, France.
We report on a case of tuberous sclerosis in a 36-year-old female
with chronic renal failure, who was treated by hemodialysis and
transplantation. The diagnosis of tuberous sclerosis was ascer-
tained by the association of typical cutaneous, retinal, and osse-
ous lesions. On the contrary, the renal changes were unusual by
their revealing symptoms, evolution, and pathology. Early hyper-
tension was exacerbated in the course of two pregnancies but
was never severe. It preceded the late onset of renal failure,
which progressed slowly. The kidneys were small, with a pecul-
iar angiographic aspect: the renal tissue was not invaded by ham-
artomas but the whole arterial bed was diffusely modified, with a
cortical perfusion defect. Both kidneys were studied after bilat-
eral nephrectomy. The lesions were far more complex than a
simple replacement of the renal tissue by angiomyolipomas: they
involved the vessels, the interstitium (with lipid inclusions sur-
rounded by a macrophagic reaction), and the glomeruli (with foc-
al and segmental sclerosis). This observation (which is the 11th
case in the literature of tuberous sclerosis with chronic renal fail-
ure and the 3rd treated by transplantation) documents a particu-
lar variety of congenital and familial nephropathy with delayed
appearance.
Nephropathy and hepatic peliosis: Vieral light chain deposition
in a pleomorphic lymphoplasmacytic malignancy analogous to
Waldenström's macroglobulinemia. F. Mignon, M. Cerf, J. L.
Preud' Homme, J. C. Brouet, and L. Morel-Maroger. Service
de Nephrologie et I.N.S.E.R.M. U 64, Hópital Tenon et
J.N.S.E.R.M. U /08 Hópital Saint Louis, Paris, France. A 38-
year-old woman was in good health until she developed portal
hypertension in May of 1978. Liver biopsy showed sinusoidal
ectasia and widening of Disse spaces consistent with peliosis he-
patis. In addition, there were amorphous, nonamyloid deposits
along the sinusoids and in the Disse spaces, which exhibited a
very dim staining for anti-kappa serum. After cavography, the
patient underwent reversible anuria. Later, proteinuria without
hematuria and renal failure was detected, and renal biopsy
showed widespread glomerular and tubular deposits with a
strong fixation of the anti-kappa conjugate along the tubular
basement membranes. These findings led to search for a lymph-
oid malignancy. Marrow biopsy showed a pleomorphic lympho-
plasmocytic proliferation analogous to that of Waldenström's
macroglobulinemia. But no serum and urine monoclonal Ig could
be detected on repeated examinations. Biosynthesis experiments
allowed the conclusion that the cells synthesized normal size Sig
which were virtually nonsecreted, and abnormally short K
chains. There was a considerable difference between the appar-
ent modecular weights of the short light chains in the cyto-
plasmic and excreted chains. The patient died rapidly with hepat-
ic failure and hypercalcemia. In conclusion, our patient present-
ed a lymphoplasmacytic disorder, revealed by visceral deposits.
Randall et al have described this new syndrome, called systemic
light chain deposits. In our case, biosynthesis experiments sug-
gest that the visceral lesions may be related to the deposit of
structurally altered immunoglobulin chains, synthesized by
plasma cells. In the liver, the deposits may be the cause of the
hepatic peliosis, because various injuries to the sinusoidal lining
cells are apparently able to induce the occurrence of this anatom-
ic entity.
Correlations between liver biopsy data and HB virus antigen-
emia in 108 patients treated by chronic hemodialysis. C. Naret, P.
Jungers, C. Degott, F. Degos, A. M. Couroucé, H. Kreis, andf.
Crosnier. INSERM U 25 and DepartmentofNephrology, Neck-
er Hospital, INSERM U 24 and Department of Hepatology,
Beaujon Hospital, and Centre National de Transfusion San-
guine, Paris, France. From 1969 to 1979, 108 uremic patients
treated by maintenance hemodialysis (62 males, 46 females) un-
derwent liver biopsy (LB) either because of clinical evidence of
chronic active hepatitis (59 pts) or routinely during abdominal
surgery (23 pts) or kidney transplantation (26 pts). Repeated LB
were performed in 31 pts (in 19, Ito 5 yrs after transplantation).
Liver biopsies showed chronic active hepatitis (CAH) in 20 pts
(18.9%), chronic persistent hepatitis (CPH) in 36, lobular hepa-
titis (LH) in 15, and normal liver in 37. All 20 pts with CAH (12
males, 8 females) were chronic HB5Ag carriers, with 80% of
them positive for HBeAg. None of the patients with transient or
without antigenemia was found to have CAH. Such lesions were
found in only 4 out of the 49 patients with routine LB. HLA B8
frequency was 15.3% in CAH, 16.6% in CPH, 18.8% in LH, and
24.2% in normal liver. Mean interval between initiation of dial-
ysis treatment and LB was not longer in CAH (25.1 2.8
months) than in CPH patients (36.3 3.7 months). Iterative LB
in 12 dialysis patients showed an aggravation of lesions only in 4
of the 8 persistently positive for HBsAg. Repeated LB in 19
transplanted patients showed aggravation in 10, all positive for
HBsAg. Progression to liver cirrhosis occurred in 6 patients,
with fatal outcome in 4, an overall mortality of 4%. We conclude
that in uremic hemodialyzed patients CAH lesions are found on-
ly in chronic carriers of HB5Ag. Although further progression of
liver lesions may occur during dialysis treatment and after renal
transplantation, fatal evolution is rarely observed.
Diversity of human T lymphocyte differentiation antigens. P.
Niaudet. I.N.S.E.R.M. U.192, Hôpital des Enfants-Malades,
Paris, France. To identify cell surface proteins on human T lym-
phocytes, we prepared two different heteroantisera. Cell surface
proteins were iodinated or internally labeled with amino acids.
After cell solubilization and immunoprecipitation with specific
antisera, the proteins recognized were analyzed on poly-
acrylamide gels by autoradiography or fluorography. The rabbit
antimonkey thymocyte antisera precipitated a single glycopro-
tein of 33,000 daltons and one or several polypeptides of 40 to
45,000 daltons. The rabbit anti-Sezary cell antisera reacted with
different proteins (55,000, 65,000, 90,000, 170,000 daltons). Fur-
thermore, we have shown that these various proteins are ex-
pressed differently in various T cell types (thymocytes, T-leuke-
mia, peripheral T cells). Thus, these proteins define different T
lymphocyte populations according to the stage of maturation.
The use of specific antisera that define functional subsets is of
great interest. For example it may allow identification of the cells
responsible for transplant rejection and to better analyze autoim-
mune diseases. These results could have therapeutic incidence.
Vaccine against hepatitis B in children: Prevention of hepatitis in
a pediatric hemodialysis unit. H. Nivet, J. Drucker, Ph. Maupas,
F. Dubois, P. Coursa get, A. Goudeau, J. C. Rolland, J. Pen-
gloan, Ph. Bagros, and B. Grenier. Hôpital G. de Clocheville,
Tours, France. In a pediatric hemodialysis unit, 8 children (aged
2 to 14 years) with chronic renal failure were immunized against
hepatitis B infection by means of a vaccine. The vaccine was
prepared by purification of HB5Ag from human sera and was
formalin inactivated. Six of them were undergoing periodic he-
modialysis, and two were still managed with conservative treat-
ment. Three HBsAg chronic carriers dialyzed in the unit repre-
sented a permanent risk of hepatitis B infection for the whole
unit. All the vaccinated children sero-converted for anti-HB5Ag
after vaccination. A followup from 3 to 17 months did not show
clinical, biologic, or serologic signs of hepatitis B in the vacci-
nated children. Therefore, hepatitis B vaccine in children with
chronic renal failure appeared to be safe and its potency satisfac-
tory. Presence of anti-HBs and absence of appearance of hepa-
titis B following immunization suggested that hepatitis B vaccine
represented for these children an efficient means of prevention
against hepatitis B infection.
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Vaccination against hepatitis B: A 4-year followup in an adult
hemodialysis unit. J. Pengloan, H. Nivet, M. Perrier, Ph. Bag-
ros, Ph. Maupas, A. Goudeau, P. Coursaget, and F. Dubois.
Unite d'Hémodialyse and Unite de Virologie, Service
Hémodialyse, CHU Bretonneau, Bd Tonnellé, Tours, France.
Since October 1975, 71 staff members and 92 haemodialysis pa-
tients were immunized against hepatitis B in an adult haemodial-
ysis unit. The vaccine was prepared by purification of HBsAg
from human sera and was formalin inactivated. Vaccinees were
screened for markers of HB virus infection, i.e., HBsAg, anti-
HBs, anti-HBc; serial controls of serum transaminases (A.L.T.,
A.S.T.) and of markers of auto-immunity were performed. The
vaccinated patients were followed from 6 to 50 months. No evi-
dence of autoimmunity was observed. Of staff members, 96%
sero-converted for anti-HBs; none of them evidenced clinical,
biologic, or serologic, signs of active HB infection. Of the hemo-
dialysis patients, 65.6% sero-converted for anti-HBs; none of
them became HBsAg chronic. These results were obtained de-
spite the fact that nearly 30% of the patients present in the unit at
the time of the trial were HB5Ag chronic carriers. Active immu-
nization proved to be a safe and efficient method to prevent HB
infection in a hemodialysis unit.
Plasmapheresis in systemic lupus erythematosus: Effects on im-
munologic pamameters. J. P. Pourrat, J. Lu/c, J. P. Calot, G. J.
Fournié, and J. J. Conté. Laboratoire d'Immunopatho/ogie
Rénale, Service de Néphrologie et d'Hémodia/yse. C.H.U. Tou-
louse-Purpan, Toulouse, Cedex, France. Twelve patients with
systemic lupus erythematosus were treated by plasma ex-
changes. All had histologic evidence of lupus nephritis. The
plasma exchanges were always performed during an acute phase
of the disease (renal or/and extra-renal) with classical immuno-
logic disorders (presence of anti-DNA antibodies and of circulat-
ing immune complexes). The effects of the plasma exchanges on
serum immune complexes, anti-DNA antibodies, and com-
plement components were studied during and after the plasma
exchanges. Circulating immune complexes (determined by the
fluid phase Clq-binding test) that were found in all patients before
the exchanges, disappeared in most cases after ten daily ex-
changes of 4 liters. After the plasma exchanges, various kinetics
of variations of circulating immune complexes were observed.
The levels of anti-DNA antibodies were modified to a lesser ex-
tent: high levels may remain after exchanges up to 40 liters. After
several weeks, anti-DNA antibody levels were frequently as high
as they were before plasmapheresis in the absence of additional
immunosuppressive treatment. The complement component lev-
els were directly lowered by the plasma exchanges, and their
study appeared of limited interest. A clinical improvement was
generally observed, but in the absence of a control group of pa-
tients, no definite conclusion on the clinical improvement after
plasmapheresis can be drawn from this study. The place of plas-
mapheresis in the treatment of patients suffering from systemic
lupus erythematosus remains to be more precisely defined.
Proximal tubular siderosis in paroxysmal nocturnal hemoglobin-
uria. P. Simon, M. P. Ramée, A. Gouazic, M. Ben-Zenou.
Centre Hospita/ier, Saint -B rieuc, Ponlchaillou, Rennes, France.
A patient with paroxysmal nocturnal hemoglobinuria, who re-
quired regular blood transfusions for hemolytic episodes, had an
acute renal insufficiency after ingestion of glafenine (1.50 g dur-
ing a single day). The renal function improved spontaneously in
10 days. Renal biopsy tissue was rust colored and, on microscop-
ic examination, showed marked proximal tubular siderosis as
well as mononuclear interstial infiltrates. Immunofluorescence
was negative for immunoglobulin G, A, M, C3, and fibrin. After 1
year, because tubular proteinuria appeared without other func-
tional abnormalities, a new renal histologic examination was
made and showed identical lesions. Marked deposition of iron in
renal proximal tubules is typical of paroxysmal nocturnal hemo-
globinuria.
Repetitive hemodialysis by temporary venous subclavian can-
nulation. 0. Simons, F. Khazine, T. Haas, G. Dongradi, and J.
P. Fend/er. Centre Hospitalier Intercommunal de Poissy,
Poissy, France. Since January 1979, temporary access of a sub-
clavian vein has been used instead of venous femoral cannulation
(used from 1974 to 1978) and instead of Scribner's shunt (used
before 1974). In 22 chronic renal failure patients without per-
manent vascular access, a subclavian cannula is introduced by
the Seldinger technique via a subclavicular approach, and its po-
sition in the superior vena cava is checked by fluoroscopic con-
trol. Through an Y connection, extracorporeal circulation is
achieved by a single-needle device with double-head pump with-
out loss of dialysis efficiency. After each session, the cannula is
flushed with heparinized saline and kept in place under sterile
adhesive dressing. The average duration of insertion was 8
weeks and the longest 8 months and 1 week. The immediate com-
plications were: puncture of an arterial vessel, 3 (hemothorax, 1;
hemomediastinum, 1; puncture without complication, 1); pneu-
mothorax, 0. Secondary complications were: blood stream infec-
tion, 0; thrombosis of the subclavian vein, 0; clotting or kinking
of the cannula necessitating a change by reinsertion of the guide
wire without the need of a separate puncture, 9; removal of the
cannula necessitating a separate puncture, 2. The advantages of
the temporary subclavian access are: immediate use, sufficient
blood flow rate, unlimited duration of use, no need for hospital-
isation, possibility of re-use of this access in case of new shunt
problems, and preservation of blood vessels. This access must
always be preferred to the Scribner' s shunt that we have not
used since 1974; it must be preferred to the femoral access when
more than two dialysis sessions are needed. To keep insertion
complication to a minimum, the cannula should be inserted by
trained medical staff with a reliable technique.
Nephrotic syndrome following porta-caval shunt in cirrhosis: A
study of three cases. G. Touchard, D. Picaud, J. P. Saint Andre,
Ph. Co/un, 0. Pourrat, Ph. Babin, and D. Patte. Service
d'Anatomie Pathologique et Service de Néphrologie, CHU. Ho-
tel Dieu, Poitiers, France. Three cirrhotic male patients with
nephrotic syndrome after undergoing surgery for porta-caval
shunt have been studied. They were 42, 48, and 56 years old,
respectively, and did not have proteinuria before the operation.
In two patients, the serum gammaglobulin level increased after
porta-caval shunt, and renal manifestations appeared 6 months
after the operation. In the third patient, the nephrotic syndrome
appeared 4 years after shunt. Nonselective proteinuria, micro-
scopic hematuria, and moderate renal failure were constant.
Antinuclear antibodies, HB5Ag, and cryoglobulin were absent.
In two patients, a low C3 level was found. Renal biopsy showed
membranoproliferative glomerulonephritis in three patients, with
diffuse epithelial crescents in one. Mesangial and subendothelial
granular IgA deposits were found in two patients. The clinical
course was death from septicemia in one; hypertension, terminal
renal failure and hemodialysis in the second; spontaneous dis-
appearance of the nephrotic syndrome with persistent mild pro-
teinuria and renal failure in the third. These three patients sug-
gest that porta-caval shunt may play a significant pathogenetic
role in hepatic glomerulonephritis.
Carpal tunnel syndrome in hemodialysis patients. J. Zingraff, S.
Di Giu/io, S. Hafez, J. Benoit, D. Kuntz, P. Jungers, and J. L.
Funck-Brentano. Inserm U 25, and U 90 and Department of
Nephrology Necker Hospital, Department of Orthopedic Sur-
gery, Ambroise Pare Hospital and Viggo-Petersen Center,
Paris, France. Carpal tunnel syndrome (CTS) has been reported
in patients receiving regular dialysis treatment (RDT), but it was
not considered to be a common complication in this treatment.
We observed CTS in 16 hemodialysis patients (6 males, 10 fe-
males) out of more than 1000 patients who had started RDT at
Necker Hospital and associated centers between 1964 and 1979,
an overall incidence of near 2%. The mean interval between initi-
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ation of RDT and clinical evidence of CTS was 8 years (range, 4
to 12 years). CTS was bilateral in nine patients. It was never
observed in arms or legs untouched by vascular access proce-
dures. Temporary relief of symptoms (pain and/or paresthesias)
was observed after local corticosteroids infiltration. This relief,
together with nerve conduction velocity studies, permits the dif-
ferentiation of CTS from vascular steal syndrome and from acr-
oparesthesias and shoulder pain of osteoarticular origin. The car-
pal tunnel was surgically decompressed in 11 patients. Complete
recovery was obtained in all but one, suffering from synovial am-
yloidosis. In conclusion, with the increasing number of patients
on maintenance hemodialysis for more than 4 years, diagnosis of
CTS should be considered in any dialysis patient suffering from
hitherto unexplained pain in the upper limbs. In our experience,





Effects of thromboxane synthetase inhibition and thromboxane
B2 administration on glomerular function in the rat. C. Baylis.
Department of Physiology, Manchester University, Manchester,
England. The normal rat kidney possesses the enzymes neces-
sary to synthesize the potent vasoconstrictor and proplatelet ag-
gregating agent thromboxane A2 (TXA2), and its stable and less
potent metabolite thromboxane B2 (TXB2). It is not at present
known, however, whether thromboxane (TX) synthesis is acti-
vated in the normal kidney, or what effect TX has on renal func-
tion in vivo. The following experiments were performed to inves-
tigate these questions. Micropuncture experiments were carried
out on 7 adult male Munich-Wistar rats (a strain that possesses
glomeruli on the kidney surface) in control conditions and again
during i.v. infusion of imidazole (0.05 mmoles/kglmin). In vitro
studies have indicated that imidazole is a potent TX-synthetase
inhibitor. No significant change was seen in single nephron (SN)
GFR or in single glomerular plasma flow rate (QA) with imida-
zole. Protein concentration (C) in afferent glomerular blood (CA)
fell slightly, but efferent glomerular protein concentration (CE)
was not significantly affected by the drug. The mean hydrostatic
pressure difference across the glomerular capillary wall, P, rose
markedly from 35 2 to 45 1 mm Hg (P <0.25, paired t test),
due largely to increased glomerular capillary hydrostatic pres-
sure (P0). In control conditions, rats were at filtration pressure
equilibrium (i.e. P oncotic pressure of efferent glomerular
blood, HE), and only minimum values of the glomerular capillary
ultrafiltration coefficient (K2) could be calculated. Filtration pres-
sure disequilibrium (P > HE) obtained during imidazole in-
fusion and exact values of K2 could be calculated. K2, the product
of glomerular water permeability and available filtration surface
area, averaged a minimum of 0.105 0.01 nll(secmm Hg) in
control conditions and fell significantly to 0.057 0.005 nI/
(secmm Hg) during imidazole infusion (P <0.005). Mean femo-
ral arterial blood pressure (AP) also rose significantly with imida-
zole from 113 4 to 131 4mm Hg (P <0.001). Inhibition of a
potent vasoconstrictor system would be expected to increase QA
and SNGFR; thus, the lack of change in these variables during
TX-synthetase inhibition with imidazole may suggest that little
or no TX is synthesized under normal conditions in the rat kid-
ney. A selective inhibitor of vasoconstrictor TX would however
reduce, rather than raise AP, and since increases in blood pres-
sure were seen with imidazole it seems likely that this drug ex-
erts additional actions in vivo. Similar experiments were carried
out on 6 additional rats in which TXB2 (100 jg/kg/min) was in-
fused into the aorta above the left renal artery. A significant fall
was seen in SNGFR with TXB2 (from 34.7 4.7 to 26.4 4.2 nl/
mm, P <0.005) and QA also declined (from 111.6 16.1 to 91.2
12.6 nI/mm, P = 0.05, N = 5). A small but significant increase
occurred in CA (from 5.7 0.2 to 6.2 0.2 g/dl, P <0.005) while
CE did not change. The value of AP was unaffected by TXB2, and
although a slight increase in AP was seen, this was not statistical-
ly significant. Rats remained at filtration pressure equilibrium
during TXB2 infusion, and thus exact values of K2 could not be
calculated. The decline in SNGFR seen during TXB2 infusion
was due both to falls in QA and increases in CA, the latter increas-
ing the oncotic opposition to the ultrafiltration process. Thus, it
seems that TXB2 exerts mild renal vasoconstrictor effects at the
large doses that were administered in these experiments.
Role of the major histocompatibility system in idiopathic mem-
branous nephropathy: Prediction of outcome and response to
treatment. S. A. Cairns, P. Klouda, P. A. Dyer, J. Manos, N. P.
Mallick, and R. Harris. Department of Renal Medicine, Man-
chester Royal Infirmary, and Department of Medical Genetics,
St. Mary's Hospital, Manchester, England. We have demon-
strated a relationship between idiopathic membranous nephropa-
thy (IMN), the major histocompatibility system (MHS) antigen
HLA-DRW3, and complement factor B allotype BfFl. Like the
MHS, factor B is coded on chromosome 6, and, in our series
delta values suggest that BfFI, DRW3, and B18 exist as a hap-
lotype. The clinical course of 40 patients with IMN, followed for
between 2 and 23 years, has been studied in relation to immuno-
genetic markers (Table). The clinical presentation was similar in
the three groups and there was no difference in incidence of fa-
milial renal disease or immunochemical abnormalities. Patients
in group I had a worse prognosis than those in groups II and III;
none remitted, while over 50% of those in groups II and III did (P
= 0.009, Fisher's exact test). Interestingly, one third of those
remitting subsequently relapsed. Decline in renal function oc-
curred in 71% of group! patients but occurred less frequently in
groups 11(22%) and III (33%) (P 0.026).
Group No. of patients B18 BfFI DRW-3
II 22
III 7
7 + + +
+ +
1 — + +
2 + — —
Eighteen of the patients received steroids. Improvement in renal
function and/or decline in proteinuria occurred in 6, 5 of whom
were in group II (DRW3 positive, BfFl negative). None of 3 pa-
tients treated in group I responded. IMN is immunogenetically
heterogeneous, and immunogenetic markers may prove valuable
in determining disease outcome. The suggestion from our data
that patients responsive to treatment may be identified by MHS
I
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